ORO CLEAR MOUTHWASH

Country: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

CHLORHEXIDINE GLUCONATE

Fáanlegur frá:

GERMIPHENE CORPORATION

ATC númer:

A01AB03

INN (Alþjóðlegt nafn):

CHLORHEXIDINE

Skammtar:

0.12%

Lyfjaform:

MOUTHWASH

Samsetning:

CHLORHEXIDINE GLUCONATE 0.12%

Stjórnsýsluleið:

BUCCAL

Einingar í pakka:

500ML/4L

Gerð lyfseðils:

Prescription

Lækningarsvæði:

MISCELLANEOUS ANTI-INFECTIVES

Vörulýsing:

Active ingredient group (AIG) number: 0107629007; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2007-02-21

Vara einkenni

_ _
_Appendix E- Product Monograph Template Standard _
_Page 1 of 16_
PRODUCT MONOGRAPH
Pr ORO CLEAR
®
Chlorhexidine Gluconate Oral Rinse, 0.12% w/v House Standard
Antigingivitis Oral Rinse
Germiphene Corporation
1379 Colborne Street East, Brantford, ON N3T 5M1>
www.germiphene.com
Date of Preparation:
February 15, 2007
Date of Revision:
November 2, 2015
Submission Control No: 161506
© 2015 Germiphene Corporation
All trademarks used under license.
_ _
_Appendix E- Product Monograph Template Standard _
_Page 2 of 16_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
3
WARNINGS AND PRECAUTIONS
..............................................................................................
3
ADVERSE REACTIONS
................................................................................................................
4
DRUG INTERACTIONS
................................................................................................................
5
DOSAGE AND ADMINISTRATION
............................................................................................
6
OVERDOSAGE
..............................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
..........................................................................
7
STORAGE AND STABILITY
........................................................................................................
7
SPECIAL HANDLING INSTRUCTIONS
.....................................................................................
7
DOSAGE FORMS, COMPO